ConductScience.org, home

Comparison · NCT02850601-deaths

Dexamethasone Solution vs Dexamethasone Solution in Mucolox™: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dexamethasone Solution vs Dexamethasone Solution in Mucolox™: deaths from any cause. Trial comparisons, record NCT02850601-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02850601-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.00000000000000002780.242wilson
Risk in group 200.00000000000000002780.242wilson
Risk difference, group 1 minus group 20-0.2420.242newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dexamethasone SolutionDexamethasone 0.5 mg/mL, 5ml TID for 4 weeks~Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate012EG000
Group 2Dexamethasone Solution in Mucolox™Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks~Dexamethasone: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate012EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Onset of symptoms were reported 4-5 days after initiating the treatment and lasted 24h. The treatment was interrupted for 2 days and resumed thereafter with no recurrence or any other adverse event. The subject was monitored through study completion (4 weeks after baseline).

Source ClinicalTrials.gov

Trial

Title
Dexamethasone Solution for the Treatment of Oral Lichen Planus
NCT number
NCT02850601
Phases
PHASE2
Conditions
Lichen Planus
Interventions
Dexamethasone
Lead sponsor
Brigham and Women's Hospital
Results first posted
2021-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02850601-deaths